TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington’s disease

• Published in: Biochemical and biophysical research communications 2012-08, Vol.424 (3), p.404-408
• Main Authors: Lee, Ji-Hyun, Lee, Jong-Min, Ramos, Eliana Marisa, Gillis, Tammy, Mysore, Jayalakshmi S., Kishikawa, Shotaro, Hadzi, Tiffany, Hendricks, Audrey E., Hayden, Michael R., Morrison, Patrick J., Nance, Martha, Ross, Christopher A., Margolis, Russell L., Squitieri, Ferdinando, Gellera, Cinzia, Gomez-Tortosa, Estrella, Ayuso, Carmen, Suchowersky, Oksana, Trent, Ronald J., McCusker, Elizabeth, Novelletto, Andrea, Frontali, Marina, Jones, Randi, Ashizawa, Tetsuo, Frank, Samuel, Saint-Hilaire, Marie-Helene, Hersch, Steven M., Rosas, Herminia D., Lucente, Diane, Harrison, Madaline B., Zanko, Andrea, Abramson, Ruth K., Marder, Karen, Sequeiros, Jorge, Bernhard Landwehrmeyer, G., Shoulson, Ira, Myers, Richard H., MacDonald, Marcy E., Gusella, James F.
• Format: Article
• Language: English
• Subjects: 3' Untranslated Regions - genetics; Adolescent; Adult; Age at onset; Age of Onset; Aged; Aged, 80 and over; Alleles; Child; Child, Preschool; Codon, Terminator - genetics; Female; Genetic modifier; GluK2 Kainate Receptor; GRIK2; Humans; Huntington Disease - genetics; Huntington’s disease (HD); Male; Middle Aged; Polymorphism, Genetic; Receptors, Kainic Acid - genetics; Trinucleotide Repeats - genetics; Young Adult
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2012.06.120

► Identification of genetic modifiers of HD could provide clues to disease-modifying treatments. ► We investigated GRIK2 as a reported modifier of age at onset in HD. ► We used a much larger sample from multiple cohorts than in previous studies. ► We also applied comprehensive analytical methods. ► We detected no evidence of an influence of the previously suggested GRIK2 polymorphism on AO in HD. Huntington’s disease is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat whose length is the major determinant of age at onset but remaining variation appears to be due in part to the effect of genetic modifiers. GRIK2, which encodes GluR6, a mediator of excitatory neurotransmission in the brain, has been suggested in several studies to be a modifier gene based upon a 3’ untranslated region TAA trinucleotide repeat polymorphism. Prior to investing in detailed studies of the functional impact of this polymorphism, we sought to confirm its effect on age at onset in a much larger dataset than in previous investigations. We genotyped the HD CAG repeat and the GRIK2 TAA repeat in DNA samples from 2,911 Huntington’s disease subjects with known age at onset, and tested for a potential modifier effect of GRIK2 using a variety of statistical approaches. Unlike previous reports, we detected no evidence of an influence of the GRIK2 TAA repeat polymorphism on age at motor onset. Similarly, the GRIK2 polymorphism did not show significant modifier effect on psychiatric and cognitive age at onset in HD. Comprehensive analytical methods applied to a much larger sample than in previous studies do not support a role for GRIK2 as a genetic modifier of age at onset of clinical symptoms in Huntington’s disease.